Suja Hiriyanna

This inventor holds 5 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Suja Hiriyanna. Retrieved from https://idiyas.com/inventor/suja-hiriyanna

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

5 out of 3,696

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

Years Active: 2019-2026

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12721908 - GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES (2026-09-01),

2. 11617801 - RP2 and RPGR vectors for treating X-linked retinitis pigmentosa (2023-04-04),

3. 11421219 - Methods and compositions for treating Leber congenital amaurosis (2022-08-23),

4. 10646588 - RP2 and RPGR vectors for treating X-linked retinitis pigmentosa (2020-05-12),

5. 10351844 - Methods and compositions for treating leber congenital amaurosis (2019-07-16),

Title: Suja Hiriyanna: Innovator in Gene Therapy

Introduction

Suja Hiriyanna is a prominent inventor based in Boyds, Maryland, known for her significant contributions to the field of gene therapy. With a total of four patents to her name, she has made remarkable strides in developing innovative treatments for eye diseases.

Latest Patents

Among her latest patents are the RP2 and RPGR vectors for treating X-linked retinitis pigmentosa. These patents disclose adeno-associated virus (AAV) vectors that comprise a nucleotide sequence encoding RP2 or RPGR-ORF15, along with related pharmaceutical compositions. The patents also detail methods for treating or preventing X-linked retinitis pigmentosa, increasing photoreceptor numbers in the retina of mammals, and enhancing visual acuity. Additionally, she has developed methods and compositions for treating Leber congenital amaurosis, which include expression vectors, viral particles, and therapeutic methods aimed at improving visual function in patients suffering from eye diseases caused by the failure to produce specific proteins.

Career Highlights

Suja has worked with esteemed organizations, including the National Institutes of Health, a component of the U.S. Department of Health & Human Services. Her work has been pivotal in advancing the understanding and treatment of genetic eye disorders.

Collaborations

Throughout her career, Suja has collaborated with notable colleagues, including Zhijian Wu and Anand Swaroop, contributing to a rich exchange of ideas and innovations in her field.

Conclusion

Suja Hiriyanna's work in gene therapy exemplifies the impact of innovative research on treating genetic eye diseases. Her patents and collaborations highlight her commitment to improving visual health and advancing medical science.

Profile summary based on public USPTO records.